Brain Aneurysm
Conditions
Keywords
Endovascular, Brain Aneurysm
Brief summary
An observational post-market, open label, multicenter Observatory. The decision to use a WEB device to treat the patients has been made before and independently of the decision to include the patient in the French Observatory.
Detailed description
Subjects will be screened for Observatory eligibility after giving informed consent. The embolization procedure will be performed in the digital angiographic suite using standard angiographic techniques. Initial analysis of Observatory data will be performed at completion of 12 month follow-up for the first thirty-five (35) subjects. Subjects will be followed per Institution's standard of care.
Interventions
WEB Aneurysm Embolization System
Sponsors
Microvention-Terumo, Inc.
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. The decision to use a WEB device to treat the patients has been made before and independently of the decision to include the patient in the French Observatory 2. Subject must be ≥ 18 years of age; 3. Subject must have an intracranial aneurysm requiring treatment according to a multidisciplinary decision. If the subject has an additional aneurysm requiring treatment, the additional aneurysm must not require treatment within 30 days of the index procedure; 4. Aneurysm to be treated must have the following characteristics: i. Morphology - saccular ii. Location: * Basilar apex (BA), or * Middle cerebral artery (MCA) bifurcation, or * Internal carotid artery (ICA) terminus * Anterior communicating artery (ACom) * Anterior cerebral Artery (ACA) iii. Diameter and width of the aneurysm is appropriate size for treatment with the WEB Aneurysm Embolization System per device Instructions for Use iv. Dome-to-Neck (DN) ratio ≥ 1.0 5. Subject must be considered by the physician to be available for subsequent visits; 6. Subject must be able to comply with all aspects of the screening, evaluation, treatment, and the post-procedure follow-up schedule; 7. Subject must sign and date CPP and/or CCTIRS/CNIL approved written informed consent prior to initiation of any clinical evaluation procedures, including screening procedures (if unable to sign for self, legal representative may do so where applicable). Additional inclusion criterion for ruptured aneurysms: For subjects with ruptured aneurysm: subject has ruptured aneurysm with Hunt & Hess Score of I, II, or III
Exclusion criteria
* 1\. Subject is greater than 75 years of age; 2. Subject has more than one aneurysm requiring treatment within 30 days of index procedure; 3. Subject is female and pregnant or breast-feeding; 4. Subject has a known coagulopathy; 5. Subject has a known hemoglobinopathy or thrombocytopathy; 6. Subject has lesion with characteristics unsuitable for endovascular treatment; 7. Subject has vessel, tortuosity or morphology which could preclude safe access and support during treatment with clinical evaluation device; 8. Subject exhibits ischemic symptoms such as transient ischemic attacks, minor strokes, stroke-in-evolution within 30 days prior to enrollment; 9. Subject exhibits clinical or angiographic evidence of vasospasm; 10. Subject has physical, neurologic or psychiatric conditions, which preclude Subject's ability to comply with all aspects of the screening, evaluation, treatment, and the post-procedure follow-up schedule; 11. Subject has known hypersensitivity to any component of the clinical evaluation device, procedural materials, or medications commonly used during the procedure; 12. Subject has received any investigational device for treatment of the target intracranial aneurysm prior to entry into this trial; 13. Subject has an acute life-threatening illness other than the neurological disease to be treated in this trial; 14. Subject has a life expectancy of less than 2 years due to other illness or condition (in addition to an intracranial aneurysm); Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Durability of aneurysm occlusion | 12 months | The following efficacy assessments will be performed to assess the efficacy of the WEB Aneurysm Embolization System in the endovascular treatment of aneurysms. 1\. Durability of occlusion compared to post-procedure imaging Durability is defined as: i. No worsening of Raymond Class from post-procedure result to follow-up result and ii. Not classified as Recanalized |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence/recanalization rate | 12 months | Rate of aneurysm recanalization |
Other
| Measure | Time frame |
|---|---|
| Modified Raymond Scale | 12 months |
| Percentage occlusion | 12 months |
Countries
France
Outcome results
None listed